Paradigm Capital Reiterates $8.50 Price Target for OrganiGram (NASDAQ:OGI)
Paradigm Capital set a $8.50 price objective on OrganiGram (NASDAQ:OGI) in a report published on Thursday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.
A number of other research firms also recently weighed in on OGI. Pi Financial set a $12.00 target price on OrganiGram and gave the stock a buy rating in a report on Monday, July 15th. CIBC assumed coverage on OrganiGram in a report on Tuesday, September 24th. They set an outperformer rating and a $9.00 target price for the company. Oppenheimer assumed coverage on OrganiGram in a report on Thursday, September 5th. They set a market perform rating for the company. Jefferies Financial Group raised OrganiGram from a hold rating to a buy rating and set a $8.20 target price for the company in a report on Friday, October 11th. Finally, Zacks Investment Research raised OrganiGram from a hold rating to a buy rating and set a $4.00 target price for the company in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $8.34.
OrganiGram stock traded down $0.13 during mid-day trading on Thursday, hitting $3.60. 2,070,365 shares of the company’s stock traded hands, compared to its average volume of 2,055,533. The company has a 50 day moving average of $3.93. OrganiGram has a fifty-two week low of $2.71 and a fifty-two week high of $8.44.
OrganiGram Holdings Inc, through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders.
Featured Article: Float
Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.